Industry Disappointed With England’s Proposed Approach To Innovative Medicines Fund
Executive Summary
Initial optimism about the prospects of speeding up access to rare disease treatments through a new £340m dedicated fund has waned as companies question whether the detailed proposals are workable in practice.
You may also be interested in...
Flexibility Is Key To Making England’s Innovative Medicines Fund Work
Stakeholders are calling for NHS England and NHS Improvement (NHSE&I) and the health technology assessment body NICE to bring more flexibility into England’s new Innovative Medicines Fund, which is due for launch later in 2021.
Older Medicines Rebate Will Test UK’s New Pricing & Access Scheme
As the UK government implements a new rebate system for older medicines as part of the new pricing deal, industry trade bodies and experts suggest that exceptions will have to be made, such as higher prices or lower rebate levels for specific products.
Pressure Mounts For Agreement On New UK Voluntary Pricing Scheme
With the clock ticking on UK drug pricing negotiations, it is still unclear whether even high-level terms of a new voluntary deal will be agreed in time.